38 results about "Drug pharmacokinetics" patented technology

A method for directly delivering whereby a substance is introduced into an intradermal space within mammalian skin which involves administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm.

The invention pertains to methods and devices for controlling the pharmacokinetics of administered substances, particularly therapeutic substances by combining advantages of delivery to two or more compartments within the skin. The invention provides methods and devices for delivering substances to subcutaneous and intradermal compartments of the skin to achieve a hybrid pharmacokinetic profile that has a portion similar to that achieved by intradermal delivery, e.g., rapid and high peak onset levels of the substance, and a portion similar to that achieved by subcutaneous delivery, e.g., longer circulating levels of the substance.

The invention provides a lipid carrier, an indissolvable pharmaceutical composition and a preparation method thereof. The composition includes a self-microemulsion indissolvable pharmaceutical composition and a composition composed of a solid lipid nanoparticle carrier and an indissolvable pharmaceutical. The self-microemulsion indissolvable pharmaceutical composition comprises, by weight, 0.05%-10% of an indissolvable pharmaceutical, 5%-60% of a liquid lipid, 20%-50% of a surfactant and 10%-35% of a cosurfactant; the composition composed of a solid lipid nanoparticle carrier and an indissolvable pharmaceutical comprises, by weight, 0.05%-5% of the indissolvable pharmaceutical, 40%-60% of a solid lipid and 30%-59% of the surfactant. By changing the type and the proportion of the lipid in the composition composed of a solid lipid nanoparticle carrier and an indissolvable pharmaceutical, the degree of hydrolysis can be controlled between 3%-90%, wherein the hydrolysis is carried out with a lipase. Because that the releasing rate of the indissolvable pharmaceutical in the lipid carrier is related to the hydrolysis of the lipid carrier, the purpose of changing the pharmacokinetics of the indissolvable pharmaceutical is achieved by controlling the hydrolysis rate of the lipid carrier.

The present invention relates to Sulfonamide Derivatives of Formula (I):

and pharmaceutically acceptable salts thereof, wherein A, W, X, R¹, R², R³, R⁴ and R⁵ are as defined herein. The present invention also relates to compositions comprising at least one Sulfonamide Derivative, and methods of using the Sulfonamide Derivatives for improving the pharmacokinetics of a drug.

The invention provides a method for catalytic conversion of a cyano group into deuterated methyl, a prepared aromatic deuterated methyl compound and an application of the compound. The method comprises the steps as follows: an aromatic cyano compound reacts to produce the aromatic deuterated methyl compound under the action of a metal catalyst with deuterium gas serving as a deuterium source. The cyano group is directly catalyzed into deuterated methyl with the deuterium gas serving as the deuterium source, the operation is simple, the raw material is cheap and easy to obtain, the reaction yield is high, the product deuteration rate is high, and the method can be applied to mass production. The prepared aromatic deuterated methyl compound can be used as a deuterated medicine or can be used for preparation of a deuterated medicine or deuterated medicine composition, and the pharmacokinetics, pharmacodynamics or metabolism toxicity of the medicine can be reduced while the medicine molecular activity is kept unchanged basically.

The present invention is directed to the production, breeding and use of transgenic non-human animals such as mice in which specific genes or portions of genes have been replaced by homologues from another animal to make the physiology of the animals so modified more like that of the other animal with respect to drug pharmacokinetics and metabolism. The invention also extends to the use of the genetically modified non-human animals of the invention for pharmacological and/or toxicological studies.

The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R¹ and R² are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

A method of using Raman imaging microscopy to evaluate drug actions in living cells is disclosed. Specifically the invention describes the methods of using Raman imaging microscopy to detect drug uptake, distribution, binding, and metabolism in a single cell, and to study drug pharmacokinetics at the cellular level. The method involves measuring the Raman image of both the drug and the cell. Control images and post-treatment images of the cell were studied. Ratio images were calculated and the requisite information was obtained from a study of the intensity of the bright areas in the ratio images.

The invention provides a drug carrier, a brain-targeted nano drug based on CRISPR gene editing technology, and a preparation method and application of the drag carrier and nano drug. The nano drug provided in the invention contains nanoparticles prepared by coupling Cas9/sgRNA and a drug carrier, the cutting efficiency of Cas9/sgRNA is high, the Angiopep polypeptide in the drug carrier helps to cross the blood-brain barrier (BBB) and target to brain tumor cells, PEG can effectively prolong the blood circulation cycle and has good biocompatibility, Guanidine group Gu+ can combine riboprotein complex not only through electrostatic interaction, but also through forming salt bridges and hydrogen bonds, the stability of nano drugs can enhanced by a small amount of fluorine, and the half-life ofnano drug pharmacokinetics is greatly prolonged. The therapeutic drug can be effectively transported to the lesion site by using the drug carrier. The nano drug can perform tumor suppression and treatment at gene level.

A method for modifying the pharmacokinetics of a pharmacologically active agent that undergoes direct N-glucuronidation by UDP-glucuronosyltransferase isoenzyme UGT2B10 in a human subject comprising administering an effective amount of an UGT2B10 modulator to said human subject. A method for identifying compounds which are directly metabolized by UGT2B10 or which act as UGT2B10 modulators is also disclosed.

The invention provides a capillary electrophoresis in-vivo detection method for cobra neurotoxin. The method comprises the following steps of: performing efficient capillary electrophoresis detection on a to-be-detected plasma sample containing FITC-NT (fluorescent single labeled neurotoxin); performing laser induction of a fluorescence detector to detect to obtain an electrophoretogram of the to-be-detected sample; and then comparing the electrophoretogram with a standard curve and calculating concentration of FITC-NT in the to-be-detected sample, wherein the conditions of efficient capillary electrophoresis are as follows: a CEofixTMMEKC kit serves as a buffer liquid, the separating voltage is 20kV, the temperature is 24 DEG C, and the detected wavelengths as follows: the excitation wavelength is 488nm and the emitting wavelength is 520nm. The in-vivo analysis method of FITC-NT, provided by the invention, is high in accuracy, high in precision and good in stability, can quickly and accurately detect neurotoxin in in-vivo blood samples, is high in detection sensitivity and very low in detection limit, can accurately and quantitatively detect a trace amount of FITC-NT components in the blood samples, can be used for in-vivo drug pharmacokinetic research of neurotoxin, and provides accurate data support.

The invention belongs to the field of innovative drug research and development, and particularly discloses a pharmacokinetics-based comprehensive early druggability evaluation method and application thereof. The method comprises the following steps: firstly, calculating a molecular descriptor of a to-be-evaluated drug, and secondly, inputting the molecular descriptor of the to-be-evaluated drug into a drug pharmacokinetics model obtained by training known drugs; and finally, calculating the druggability score of the to-be-evaluated drug through the output of the drug pharmacokinetic model. Themethod has few steps, performs comprehensive rapid screening based on pharmacokinetic characteristics of new drugs, provides important decision information for early drug research and development, and saves a large amount of experiment expenditure and time.

The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.

Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or complexation vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. In certain non-limiting embodiments, the use of heparosan is complexed with anti-cancer drugs and the like, thus forming a prodrug for the purposes of increasing efficacy and reducing side effects compared to the parental drug alone.

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

The invention discloses a method for establishing a prediction model for the influence of fat emulsion on kinetics in a drug body. Comprising the following steps: constructing a quantitative model of the drug binding capacity of the long-chain fat emulsion in vitro; constructing a kinetic quantitative model for distributing the medicine to the fat emulsion in vitro; the influence of fat emulsion on pharmacokinetics after quantitative drug excess; and constructing a prediction model of in-vivo pharmacokinetic behaviors through an in-vitro quantitative experiment. On the basis of the phenomenon that fat-soluble drug molecules diffuse to the fat emulsion, an isothermal titration calorimetry method and a high performance liquid chromatography analyzer are used for analyzing the diffusion phenomenon of the drug, and a reliable prediction model for predicting the drug binding capacity of the fat emulsion in vitro is established; an ultraviolet-visible spectrophotometer is used for quantitatively monitoring the speed of combining the fat emulsion with drug molecules in real time, an animal model is established to analyze the influence of the fat emulsion on pharmacokinetics of drugs, and then a prediction model of the influence of the fat emulsion on pharmacokinetics of the drugs is established through an in-vitro quantitative experiment.

The systems and methods described herein generally relate to adjusting a neurostimulation (NS) therapy based on drug pharmacokinetics of a patient. The systems and methods deliver an NS therapy to a portion of electrodes of a lead positioned proximate to neural tissue of interest, which is associated with a target region. The NS therapy is defined by stimulation parameters. The systems and methods determine a trigger event indicative of a drug being administered to a patient. The drug is configured to affect at least one of the neural tissue of interest or the target region. The systems and methods adjust one or more of the stimulation parameters based on the PS profile.